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A STUDY OF CORRELATION OF DISEASE SEVERITY BY CLINICAL 
ASSESSMENT, RADIOLOGICAL ASSESSMENT AND IgG 
RHEUMATOID FACTOR IN PATIENTS WITH RHEUMATOID 
ARTHRITIS 
                                                      ABSTRACT 
Background: Rheumatoid arthritis is a chronic, autoimmune disease of 
inflammatory nature which generally affects the joints and multiple organs and 
is often debilitating in nature. Though various studies have been done regarding 
the disease, a lot about the disease still remains unknown. 
Objective: The main aim of the study is to determine the correlation between 
the disease activity scale (DAS28) and radiological severity scale (Van der 
Heijde modification of Sharp score) in patients who present with rheumatoid 
arthritis. This study also determines the efficacy of IgG RF in determining 
radiological progression in the same patients.  
Materials and methods: The patients were selected using the ACR/EULAR 
criteria for RA. The DAS 28 and modified Sharp’s Scale were obtained with 
consent and blood drawn and checked for IgG RF positivity along with other 
required investigations and the results studied using the statistics described in 
the study. 
Results: Though patients with increased DAS 28 scores tended to have higher 
Sharp’s scores there was no significant correlation between the two.( p=0.069 ) 
There was however a definite positive correlation between the IgG RF and 
modified Sharp’s score.( p < 0.01) 
Conclusions: Though both DAS28 and Sharp score both help to determine the 
severity of the disease, they detect two different aspects of the same disease and 
are hence not changeable. Sharp score and other radiological scale do not 
determine of the severity of the disease but detect bony changes that predict 
long term morbidity. Though IgM RF and anti CCP are most commonly used in 
RA, IgG RF predicts radiological changes like bony erosions and joint space 
narrowing and can hence be used to predict long term changes. 
Keywords: rheumatoid, arthritis, DAS28, Sharp , IgG RF, severity 
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1. INTRODUCTION: 
Rheumatoid arthritis is a chronic, autoimmune disease of inflammatory 
nature which generally affects the joints and multiple organs and is often 
debilitating in nature. Though various mechanisms of pathogenesis have been 
discussed the exact cause is not yet known. The prevalence of the disease is 
about 0.8%(0.5% - 1%)[1]  Over the years, various major discoveries have lead 
us to bring about earlier diagnosis of RA and manage those patients better. 
 The advent of DMARDs and later biologics has changed the way of 
treatment of RA.[2] With various modes of treatment available it has now 
become essential for us to estimate the extent and the severity of the disease 
initially during presentation to plan our management. It is also very important to 
have proper universal scales to determine effectiveness of the treatment given 
and estimate prognosis.[3] 
 There are various ways to determine the severity of the disease. In 
clinical practice physicians tend to check the severity of the disease as well as 
detect prognosis and response to drugs using certain scoring systems. The 
commonly used clinical severity scales for both practise and clinical trials tend 
to use factors like swollen joints, tender joints, markers of inflammation and 
various questionnaires giving what the patient feels about the disability.[4,5] 
These scores generally give a very good idea about the acute pathological 
process and immediate and short term response to drugs. However a major part 
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of the pathogenesis of RA is the long term complications especially on the 
joints which lead to permanent and debilitating disability. Hence radiological 
investigations like radiographs have always been a major part of the 
management of the disease.[6] There is however no clear indication about how 
the various clinical severity scores and radiograph scores tend to correlate. 
Some literature states that clinical disability as measured by the clinical scales is 
an acute pathology which is differs from the chronic pathology which causes 
radiological changes like erosions.[7,8] There is another view which states that 
there is a proper correlation between the two scoring systems with regard to 
patient’s disease. However further studies are needed.  
Also the role of positivity of antibodies specific to RA and their 
correlation with the severity indices is also a subject of debate with some 
studies showing that antibodies like IgG RF and anti CCP tend to correlate well 
with radiological progression of the disease.[9,10] 
This study aims to correlate the commonly used clinical severity scale 
(DAS28) and commonly used radiological scale (Van der Heijde modification 
of Sharp score) to determine if there is a positive correlation between the two. It 
also hopes to determine the efficacy of IgG RF in determining radiological 
progressions in RA. 
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2. AIM OF THE STUDY 
1. To study the correlation between the disease activity scale (DAS28) and 
the commonly used radiological severity scale (Van der Heijde 
modification of Sharp score) in patients who present with rheumatoid 
arthritis in Govt. Kilpauk Medical College, Chennai. 
2. To determine the efficacy of IgG RF in determining radiological 
progression in the same patients. 
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3. REVIEW OF LITERATURE  
3.1 HISTORICAL REVIEW: 
Rheumatoid arthritis and other associated arthritis have been documented 
in medical literature since 1500 B.C. The first mention of the disease from 
ancient scrolls comes around 1500 B.C. when the Ebers Papyrus describes a 
condition that is similar to rheumatoid arthritis. In his book “Treatise on 
Rheumatism and Rheumatoid Arthritis”, Archibald Garrod refers to bones in 
ancient skeletal findings from around the world, which includes the ruins of 
Pompei , a graveyard in Pomerania (Poland-Germany border), remains of a 
Norse Viking and from ancient Egypt.(11) In India , “Charak Samhita” (written 
as early as 500 BC) describes patients with pain and swelling of joints along 
with loss of mobility and function.(12)Descriptions about Rheumatoid arthritis 
were also given by Hippocrates in 460 B.C. and Scribonius Largus in Roman 
literature around 100 A.D. In modern medicine, Augustin Jacob Landre-
Beauvais mentioned patients who suffered from a new arthritis in 1800 and 
termed it Goutte Asthenique Primitive (Primary Asthenic Gout).(13) In 1859, 
Alfred Garrod differentiated RA from gout in his book “Treatise on Nature of 
Gout and Rheumatic Gout”(14) and later in 1890 coined the name “Rheumatoid 
Arthritis”.(15) The term Rheumatoid arthritis was then accepted by the British 
Nomenclature in 1922 and by the United States Nomenclature in 1941.(16) 
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3.2 DEFINITION: 
Rheumatoid arthritis is a chronic autoimmune disease of unknown 
etiology with multisystem involvement. Although it is mainly seen as a disease 
involving the joints it is evident that there is abnormal systemic immune 
response and this results in extra-articular manifestations. The most 
characteristic feature of Rheumatoid arthritis remains the persistent 
inflammatory synovitis involving peripheral joints usually in a symmetrical 
combination. This results in the damage of the cartilages, bony erosions and 
changes in the integrity of the joints which is the hallmark of the disease. 
3.3 EPIDEMIOLOGICAL REVIEW: 
Rheumatoid arthritis is seen all over the world, except in a few population 
like the Chinese, Pima Indians of North America, Caribbean blacks and rural 
Sub-Saharan Africans where the incidence is very low.(17) The various studies 
about the epidemiology of RA gives a population prevalence of 0.5%-1% of the 
general population which increases with age and reaches a maximum at the ages 
of 35 to 50 years.(18) There are gender differences with females affected 3 times 
more than men.(18)The prevalence of Rheumatoid Arthritis in India is found to 
be 0.75% which is similar to the disease’s prevalence seen in developed 
countries.(19)  
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3.4 ETIOLOGY: 
Though the precise cause of RA is still not known, many studies show 
that environment and genetic factors play an important role in the pathogenesis. 
3.4.1 GENETIC FACTORS 
           Among the various etiological factors, genetic factors account for about 
50% of the risk of developing rheumatoid arthritis.(20)The importance of 
genetics in RA is clearly seen from the fact that concordance rates in 
monozygotic twins is 12% to 15% when one twin is affected, compared to 4% 
for dizygotic twins and 1% for the general population.(21) Siblings of patients 
suffering from RA have a two to four  fold increased chance of developing RA 
as compared to unrelated population.(17,22) 
The most consistent and probably the most influential genetic risk factor 
is the Class II MHC haplotype of an individual. Many other genes are also 
involved and only a percentage of them have been presumed to have been 
studied. 
HLA DR4B is associated with the maximum susceptibility to RA. Others 
include HLA DR1B and HLA DR14.(23) It had been found that in some 
population about 96% of patients with RA have the susceptible HLA-DR locus. 
Some HLA genes like DRB*1301 are associated with less susceptibility to the 
disease.(24)  
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Non HLA genes(25): 
           IL-1 gene cluster 
           TNF receptors I and II 
           CTLA-4  
           Fc γ-receptor II/III loci 
           SLC22A4 
           SLC22A5 
Additional Polymorphisms(17) 
            1. Cytokine polymorphism (TNF)(26) 
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            2. PADI4(27) 
                  3. PTPN22(28)  
            4. STAT4 
            5. IL2/21 
            6. TRAF1-C5 
Having a combination of susceptible genes tend to increase the risk as 
these genes were found to interact with each other. 
3.4.2 ENVIRONMENTAL FACTORS 
1. Smoking is considered as the best defined environmental risk factor to cause 
seropositive Rheumatoid arthritis.(29) Though its mechanism is not certain it 
could possibly involve the activation of PADI and innate immunity in the 
lungs.(17) 
2. Infectious agents: Though there are no conclusive evidences, it has been 
postulated through various studies that infectious agents can trigger disease by 
activation of the innate immunity or by molecular mimicry. These include 
Mycoplasma, Parvovirus B19, Retrovirus, Mycobacterium and EBV.(17) 
Rheumatoid arthritis also appears to be related to periodontal disease due to 
Porphyromonas gingivalis which expresses PADI4.(30)  The following table 
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gives the commonly discussed infections and their potential mechanism of  
action 
 
 
                
3. Exposure to silica seen in granite workers and fish industry workers seem to 
confer increased risk for RA. 
4. Selenium and copper deficiency can increase risk of RA possibly due to 
modulation of immunity.(31) 
5. Some factors like consumption of alcohol, fish oil, olive oil and Vitamin C 
have been postulated with decreasing risk of developing RA. 
6. Usage of oral contraceptive pills is said to reduce the incidence of rheumatoid 
arthritis. 
3.4.3 HOST FACTORS: 
There is a clear gender predisposition towards females in rheumatoid 
arthritis as already explained in the epidemiology. It is postulated that sex 
hormones play a role in the pathogenesis of RA, evidenced by the increased 
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presence in females. Pregnancy tends to reduce the intensity of the disease and 
postpartum flares tend to occur. It is now postulated that hyperprolactinemia 
might be a risk factor for RA.(32) 
3.5 PATHOGENESIS  
It is believed that the starting of the pathogenesis of rheumatoid arthritis 
begins years before the symptoms of the disease come to the fore. It is believed 
that the disease is triggered by the repeated exposures of a genetically 
vulnerable host to an arthritogenic antigen. There is a continuous autoimmune 
reaction leading to CD4 helper T cells and B cells activation. These result in 
local release of inflammatory mediators and cytokines which ultimately lead to 
destruction of the joints. 
              In genetically susceptible individuals (patients with genes that break 
tolerance and results in auto reactivity), host factors and environmental factors 
(discussed above) result in repeated activation of innate immunity. The 
environmental factors are important as they lead to post transcriptional 
modifications of proteins, most important among these being the citrullination 
of arginine residues either in the synovium or in the mucosal surfaces. These 
can occur in normal individuals also, but in genetically susceptible individuals 
where tolerance is broken, this can lead to development of antibodies against 
these modified proteins notably Rheumatoid Factor antibodies (RF) and anti 
citrullinated antibodies (anti- CCP). 
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The synovium is attacked by activation of the synovial innate immunity. 
The antigen presentation done by the dendritic cells is done both in the synovial 
germinal centres and also more commonly after the dendritic cells travel 
through the lymphatics and reach the central lymphoid system. Naive T cells are 
activated and they stimulate the B cells to produce pathogenic antibodies or 
migrate to the synovium and produce inflammatory cytokines like IL-17. This 
results in repeated episodes of inflammation which then progresses to a 
destructive phase having both antigen dependent and antigen independent 
mechanisms which are mediated by mesenchymal components like 
synoviocytes and fibroblasts. As the disease progresses many cell types 
(especially fibroblasts) acting via the nuclear factor κβ (NFκβ) activate the 
NFκβ ligand (RANK/RANKL) system which activates osteoclasts. The 
osteoclasts cause bone erosions while the proteolytic enzymes released by the 
the synoviocytes and synovial fluid neutrophils cause cartilage dissolution.   
The primary inflammation site in rheumatoid arthritis is the synovium. 
Synovitis occurs when the synovial compartment is infiltrated by leucocytes 
which migrate to the synovium due to activation of endothelium of synovial 
microvessels, resulting in expression of adhesion molecules and release of 
chemokines. Neoangiogenesis caused by the cytokines and local hypoxic 
conditions along with insufficient lymphangiogenesis (which reduces cellular 
egress), are features of early synovitis. Along with these microvascular injuries, 
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the other earliest lesion in rheumatoid synovitis appears to be the increase in 
synovial lining cells. The increase in synovial lining cells can be quite high. In 
normal joints it is only 1-2 cell layer deep, while in joints inflicted with RA it 
can be 4-10 cell layers deep.(17) There are two different types of cells in the 
lining. Type A synoviocytes resemble a macrophage while Type B synoviocytes 
are fibroblast like cell. Though there is an increase in number in both the cells, 
there is much more increase in Type A cells. 
 
  PATHOGENESIS IN RHEUMATOID ARTHRITIS 
             
Adaptive immunity pathways are the epicentre of the early pathogenesis 
of RA. In microscopic examination CD4 memory cells are aggregated around 
13 
 
the post capillary venules, B cells are located within reactive lymphoid cells, 
with plasma cells and macrophages outside the centre which is consistent with T 
cell dependent B lymphocyte activation. B cell activation by CD4+ Helper T 
cells result in antibodies and immunoglobulin formation within the synovium 
and results in immune complex formation. These antibody complexes as well as 
different antibodies contribute to the synovitis. Moreover the synovial 
fibroblasts in RA release numerous enzymes like cathepsins and collagenases 
which degrade the various components of articular matrix. Besides these 
various enzymes and cells, T lymphocytes, fibroblasts, myeloid cells and 
endothelial cells of the synovium also release various cytokines and 
chemokines. These also play an important role in the pathogenesis of 
rheumatoid arthritis. 
In the synovium of patients with RA, CD4+ T cells differentiate more 
into TH1 like effector cells that produce the proinflammatory cytokines like 
IFNγ rather than differentiation into TH2 like effector cells that are capable of 
producing anti-inflammatory cytokines like IL-4. Therefore there is a 
continuous secretion of pro-inflammatory cytokine IFNγ without anti-
inflammatory cytokine IL-4 and as a result of this imbalance macrophages 
which secrete other pro-inflammatory cytokines likes IL-1 and TNF are 
activated. These macrophages also increase the expression of pro-inflammatory 
molecules. T lymphocytes express CD154 and also release a variety of 
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cytokines which promote B cell proliferation and differentiation into antibody 
forming cells. The production of RF , anti-CCP and other immunoglobulins 
which occur as a result of this leads to formation of immune complexes which 
result in activation of complements and exacerbation of inflammation by 
formation of C3a ,C5a and other anaphylatoxins.[33] 
            Beside this chronic inflammation which occurs in the synovial tissue, a 
simultaneous acute inflammatory process also occurs in the synovial fluid. 
Antibodies are produced locally in response to tissue compartments and 
immune complexes and these activate complements and also generate 
chemotactic factors and anaphylatoxins. Along with these, leukotriene B4 and 
products of complement activation also attract neutrophils. The net result of all 
these is the increased migration of polymorphonuclear leucocytes to the 
synovium. These polymorphonuclear leucocytes ingest immune complexes and 
produce reactive oxygen metabolites and other proinflammatory mediators. The 
production of large amounts of lipoxygenase and cyclo-oxygenase products by 
the cells in the synovium and its fluid further worsens the inflammation in these 
patients.[34] 
            The pathological tissue component in RA is the pannus. Pannus is a 
highly vascular granulation tissue which is composed of small blood vessels, 
proliferating fibroblasts and mononuclear cells. The synovial fluid contains 
many enzymes that can degrade the cartilages, especially in the juxta-position of 
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the pannus. Pannus can produce a large number of enzymes like stromelysin 
and collagenase which can lead to tissue damage. The macrophages and 
fibroblasts also produce PGE2 which can also contribute to bone mineralisation. 
The final common pathway that leads to bone mineralisation most likely 
involves the activation of osteoclasts that are present in large numbers at the 
site. The major agents causing the systemic manifestations of RA, which 
includes fever, malaise and increased acute phase reactants, are IL-1 and TNF. 
The immune complexes which escape the synovium can get deposited in the 
blood vessels causing vasculitic changes. 
3.6 CLINICAL FEATURES 
            There are 3 patterns of onset of the clinical picture of rheumatoid 
arthritis. 
Insidious onset – 55 % to 65% of patients with RA present with a slow 
onset disease which progresses over weeks to months.(35)They can present with 
either systemic features or joint involvements. Non specific symptoms like 
fatigue, malaise, diffuse musculoskeletal pain and swollen joints can be the 
initial presentation with specific joints involved later in the course of the 
disease. At the time of initial presentation asymmetric involvement of joints are 
common, but unlike other arthritis, RA quickly tends to involve symmetrical 
joints.(8) Symptoms tend to persist in the initially affected joints as they progress 
to other joint and hence are not truly migratory. 
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Acute onset – 8% to 15% of patients have an acute onset of presentation 
with symptoms often less symmetrical than the insidious onset of presentation. 
The differential diagnosis for this type of presentation includes sepsis and 
vasculitis. 
Intermediate onset – In 15% to 20% of people symptoms develop over 
days to weeks. Systemic symptoms are more markedly seen in these patients 
when compared to those who have an insidious onset. 
Morning stiffness is an important and characteristic sign of inflammatory 
arthritis that is frequently seen in patients with rheumatoid arthritis. It is caused 
by accumulation of oedema fluid in the inflamed tissues as the patient is 
sleeping. Once the patient wakes up and starts moving his joints, the excess 
oedema is drained by the venules and lymphatics which open up with the 
articulation of joints. Morning stiffness greater than 30 to 45 minutes is 
characteristic of inflammatory arthritis and can sometimes precede pain.  
3.6.1 Joint involvement:  
The joints frequently involved first in rheumatoid arthritis includes the 
metacarpophalangeal (MCP) joints, the proximal interphalangeal(PIP) joints 
and the wrists in the upper limbs along with the metatarsophalangeal joints in 
the lower limbs.[36] Larger joints usually become symptomatic after the small 
joints. In larger joints the synovitis appears to remain asymptomatic for a longer 
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period of time and active synovitis is seen in biopsy specimens of quiescent 
large joints.[37]   
                
 
INVOLVEMENT OF SPECIFIC JOINTS:  
Hand and wrist:  
They are considered together as they share common disabilities for the 
patient and form a functional unit. One of the earliest signs of RA is the 
swelling on the dorsal side of the wrist especially involving the tendon sheaths 
of extensor carpi ulnaris and extensor digitorum communis. Sometimes cystic 
structures on the dorsal aspect of the wrist and hands resembling a ganglion are 
early features of RA. As synovial proliferation increases within the joint, the 
pressure which is built up inside the synovium along with the enzymes begin to 
destroy tendons, ligaments and bones distal to the ulnar head. The ulnar 
collateral ligament is stretched and finally ruptures causing the ulna to cause a 
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dorsal prominence which can be depressed (piano key styloid). On the volar 
side, synovial protrusion cysts are formed and can be palpated. The hyperplastic 
synovium can compress the median nerve and cause carpal tunnel syndrome. 
One of the characteristic deformities seen in the fingers is the swan neck 
deformity which is formed by the flexion of the metacarpophalangeal (MCP) 
joint and the distal interphalangeal joint (DIP) along with hyperextension of the 
proximal phalangeal joint (PIP). It starts with the shortening of the interosseous 
muscles which causes tension on the dorsal tendon sheath. This leads to the 
hyperextension of PIP causing the characteristic deformity.[38]  Sometimes 
during the course of chronic RA, the extensor hood around the PIP may get 
avulsed due to chronic inflammation causing a boutonniere deformity. In the 
thumb, besides the boutonniere deformity, inflammation of the carpometacarpal 
joint can cause volar subluxation when contracture of the adductor hallucis 
develops. Another common presentation seen in the hand is tenosynovitis of the 
fingers like de Quervain’s tenosynovitis. Sometimes the rheumatoid nodules in 
the tendon tend to lock the fingers in a painful fixed flexion position or cause 
‘trigger’ fingers. As disease progress the there is severe resorption of bone.  
This resorption begins in the articular cartilage and extends along the diaphysis 
of the phalanges causing the digits to be shortened. As a result of these changes 
the digits are shortened, skin folds are present excessively. As the disease 
progresses the phalanges can be telescoped into each other and often pulled out 
into long extension without pain. If the patient is not properly treated the end 
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result of all these changes is bony ankylosis. Bony ankylosis is usually found in 
joints that have been immobilised either by inflammation, pain or treatment. 
Grip strength is a very sensitive indicator of hand involvement as it 
simultaneously tests multiple joints of the hands.[17] Muscular contraction in the 
grip strength test causes tightening of the ligaments around the joints, 
compressing an already inflamed synovium. The result is weakness along with 
pain due to the reflex contraction of muscles due to pain. 
 Disease of the wrist usually goes along with disease of the fingers as they 
are a combined unit. Weakness of the extensor carpi ulnaris causes radial 
deviation in the wrist. In response to this there is an ulnar deviation of the 
fingers to keep the tendons of the phalanges in a normal straight line to the 
radius. This causes the characteristic “zigzag” deformity which is seen in RA. 
Elbow:  
It is involved in 20% to 65% of the patients. One of the earliest finding 
seen in patients is loss of full extension. Fortunately this can be partially 
compensated by the actions of the shoulder joint and wrist joint. As the elbow is 
a stable hinge joint, it is rarely involved with pain but if the lateral stability is 
lost then the disability can be severe. 
Shoulder joint: 
In the shoulder, RA affects the synovium, distal third of the clavicle, 
rotator cuff, various bursa and also many muscles surrounding the joint. The 
involvement of the rotator cuff is a major cause of morbidity. Weakness of the 
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cuff leads to superior subluxation. Aging and previous injury tends to increase 
the chances of tears of the rotator cuffs. This occurs due to increased erosion by 
the proliferating synovitis. Radiographic examinations of the shoulder generally 
show erosions and superior subluxation. Sometimes there might be associated 
chronic subacromial bursitis which is not generally associated with pain or loss 
of motion. There tends to be synovial proliferation within the subdeltoid bursa 
which can explain the resorption seen on the under surface of the distal clavicle. 
Very rarely, there is rupture of the shoulder joint which presents with symptoms 
resembling obstruction of venous drainage from arm.  
Temporomandibular Joint: 
 This joint is commonly involved in RA. Studies show that 55% of RA 
patients have jaw symptoms at one time during the course of their disease. 
Radiographic studies reveal that there are structural alterations in 78% of the 
joints examined.[35] An overbite or an erosion can develop as the mandibular 
condyle along with the corresponding surface of the temporal bone, the 
eminentia articularis, is eroded. Sometimes patients have an acute pain and 
difficulty in closing the mouth which requires intra-articular glucocorticoid 
therapy to reduce the acute inflammatory process. As temporomandibular joint 
abnormalities are also commonly seen in non-rheumatoid population it is 
essential to differentiate the two. CT scan and MRI show erosions and cysts in 
the mandibular condyle which is generally specific for RA. However many 
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studies have shown that there is no correlation between the CT finding and 
clinical presentation of temporomandibular joints in patients with RA.[39] 
Cricoarytenoid Joints: 
 Careful histories in patients with RA may reveal hoarseness in about 
30% of rheumatoid patients and it is believed more patients have asymptomatic 
cricoarythenoid arthritis. Normally it is not crippling but in some patients it can 
become inflamed and immobilised and cause inspiratory stridor. Various studies 
show that there is a better correlation to mucosal and functional abnormalities 
like rheumatoid nodules seen in indirect laryngoscopy to symptoms of difficult 
inspiration rather than CT detected laryngeal abnormalities and hence indirect 
laryngoscopy is indicated in symptomatic patients.[40] 
Sternoclavicular and Manubriosternal Joints: 
 Sternoclavicular and manubriosternal joints are frequently involved in 
RA. However as they are relatively immobile they are generally asymptomatic. 
Rarely patients give history of pain in the sternoclavicular joints while lying on 
specific sides. It is important to consider superimposed sepsis when symptoms 
do occur. 
Cervical Spine : 
 Unlike other joints, the joints of the cervical spine frequently manifest 
osteochondral destruction. Though significant pain is frequently reported, in the 
absence of muscle spasm passive range of motion is frequently normal. The 
extension of the inflammatory process from the neurocentral joints into the 
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discovertebral area along with the chronic cervical instability due to apophyseal 
joint destruction lead to microfractures of the vertebral end plates, degeneration 
of disc cartilages and disc herniation. Among the bones in the cervical spine, 
there are special characteristics associated with the atlas and the atlantoaxial 
joint. 
• The atlas can move anteriorly on its axis. This is due to the laxity of the 
ligaments caused by the formation of proliferative synovial tissue in synovial 
bursae and by erosion or fracture of the odontoid process. The atlas can also 
move posteriorly on the axis. This can occur if the odontoid peg is fractured 
from the axis or if it is destroyed. The atlas can also sublux vertically in relation 
to the axis. This occurs only very rarely. This results due to destruction of either 
the lateral atlantoaxial joints or the bone around the foramen magnum. The most 
common symptom which occurs in cervical subluxation is that of pain radiating 
up to the occiput. Other clinical presentations include slowly developing spastic 
quadriparesis with sensory loss in the hands and transient episodes of medullary 
dysfunction which can present as paresthesias in the shoulders and arms during 
movement of the head. Physical findings which are suggestive of atlantoaxial 
subluxation are loss of occipitocervical lordosis, resistance to passive spine 
motion along with abnormal protrusion of the axial arch which can be felt by 
our finger along the posterior pharyngeal wall.  
Symptoms of spinal cord compression for which we should consider 
intervention are syncope, altered consciousness, loss of sphincter control, 
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dysphagia, convulsions, vertigo, hemiplegia, dysarthria, nystagmus, and 
peripheral paresthesias. Studies show that the progression of peripheral joint 
erosions in patients with RA parallels that of cervical spine .The two coincide in 
both severity and timing. 
Thoracic, Lumbar, and Sacral Spine :  
These portions of the spine are generally spared in RA. Exceptions 
include the apophyseal joints where rarely synovial cysts seen at the joint can 
impinge like an epidural mass on the spinal cord which causes pain, neurologic 
deficits or both. 
Hips:  
The hip is more frequently involved in juvenile RA than in adult onset 
RA. Symptoms of hip synovitis include pain in the lower buttocks or in the 
groin. Sometimes patients have trochanteric bursitis which presents as pain on 
the lateral aspect of the hip. About 50% of patients with well-established RA 
have radiological evidence of hip disease. In RA the symmetrical thinning of 
the cartilage lead to axial migration. Rarely there is collapse and resorption of 
the femoral head, resulting in the remodelling of the acetabulum which is 
pushed medially causing protrusio acetabuli.[41] Loss of internal rotation seen by 
physical examination  correlates well with X rays and MRI. Similar to other 
weight-bearing joints, the femoral head can develop few cystic lesions that tend 
to communicate with the joint space. 
 
24 
 
Knees:  
Synovial inflammation and its effects in the knees can be easily picked up 
by physical examination. As early as 1 week after the onset of symptoms 
noticeable quadriceps atrophy is present and this leads to the application of 
greater force through the patella to the femoral surface. Another early 
manifestation of knee disease seen in patients with RA is loss of full extension 
which is initially a functional loss that later tends to become a fixed flexion 
contracture unless early corrective measures are undertaken. 
Flexion of a knee with a large effusion (secondary to synovial 
inflammation) tends to markedly increases intra-articular pressure. This 
increased intra-articular pressure may then cause a small out pouching of 
posterior components of the knee joint thus producing a Baker’s cyst or a 
popliteal cyst. If the intra-articular pressure is persistently high the cyst may 
then rupture or dissect into the calf or into the posterior thigh. An unruptured 
popliteal cyst can compress superficial 
venous flow from the lower leg and produce dilation of superficial veins along 
with edema.[42] Rupture of the joint along with extravasation of the fluid into the 
calf can present with swelling and tenderness along with systemic signs of fever 
with leukocytosis. This can be differentiated from its differential diagnosis of 
acute thrombophlebitis by the appearance of a crescentric hematoma which 
occurs beneath one of the malleoli of the ankle.[43] 
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Ankles and Feet: 
Ankle involvement is generally mild in patients with RA but damage 
occurs in severe progressive forms of the disease. Clinical presentations include 
cystic swellings anterior and posterior to the malleoli. In rheumatoid arthritis the 
inflammation and proliferation which occurs in the disease affects the joints by 
stretching and eroding the ligaments in the ankle thus affecting the stability of 
the joint. This can result in incongruity which can progress to pronation 
deformities along with eversion of the foot. The Achilles tendon can be 
involved by the formation of rheumatoid nodules on it or if diffuse 
granulomatous in the tendon causes spontaneous rupture.[44] Patients with RA 
tend to have more pain when walking on an uneven ground due to subtalar joint 
involvement which is commonly involved. As the eversion progresses in the 
subtalar joint it can lead to subluxation and lead to rocker bottom foot 
deformity. Disease of the mid foot can lead to collapse of the arch causing 
difficulty in walking. Metatarsophalangeal joints are frequently involved in RA 
and are the initial sites of erosions in many patients. Downward subluxation of 
the metatarsal heads can occur after the MTP joints become involved which 
produce “cock-up” toe deformities of the proximal interphalangeal joints. If the 
disease continues untreated it can lead to hallux valgus and bunion formation. 
Sometimes cystic collections develop under the MTP joints.[45]Patients who 
have for a chronic period of time subluxation of metatarsal heads can develop 
pressure necrosis on the plantar surfaces of the feet. Also those who present 
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with subluxation of MTP joints develop ulceration which occur over the PIP 
joints that protrude dorsally (hammer toes). The net result of this is increased 
pressure on the MTP joints which causes a sensation described as “walking on 
marbles” by the patients. Changes caused by the disease include stretching of 
the intermetatarsal joint ligament in response to inflammation, anterior 
migration of the plantar fat pad, spreading of the forefoot and dorsal subluxation 
of toes which is followed by plantar subluxation of the metatarsal heads.[46] DIP 
joints of the foot are not usually affected in RA. Tarsal tunnel syndrome occurs 
in RA patients and cause foot pain. 
 
3.6.2 EXTRA ARTICULAR MANIFESTATIONS 
 Around 40% of patients with rheumatoid arthritis tend to develop extra-
articular manifestations.[47]The risk ratio of mortality which is seen in RA 
patients who also have extra-articular manifestations is five times more than the 
patients who do not have the same. Patients with RA particularly tend to have 
increased risk of premature death due to cardiovascular disease.[48] Other factors 
which have been found to be associated with extra articular manifestations are 
smoking[49] and HLA DRB1.[50] Rheumatoid nodules also tend to have 
associations with severe extra-articular disease. 
1. Constitutional features: 
 Fatigability and weight loss are frequently present in the early stages of 
the disease. 
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2. Rheumatoid nodules: 
 Rheumatoid nodules are predominantly present in sero-positive patients 
rather than sero-negative patients. The most common sites are elbows, finger 
joints, ischial and sacral prominence, occipital scalp and Achilles tendon.  
3. Haematological manifestations: 
 Anaemia in RA is caused by a number of factors like abnormal iron 
metabolism, chronic inflammation and increased phagocytosis of RBC in spleen 
and synovium. Though the actual cause is not known, thrombocytosis is 
frequently seen in RA. Sometimes thrombocytopenia is seen due to either drug 
therapy or as a part of Felty’s syndrome. Eosinophilia has been found to be 
associated with extra-articular manifestations including pulmonary 
complications.[51] 
4. Felty’s syndrome: 
 Felty’s syndrome is defined as RA in combination with splenomegaly and 
leucopenia. It is often present long standing RA. It is more commonly seen in 
seropositive RA and is associated with nodular deforming RA. As a result of 
leucopenia, bacterial infections are common and they increase the mortality 
rates. 
5. Hepatic abnormalities:  
 Increased liver function abnormalities are also found commonly in RA 
and they parallel the haematological changes in active RA such as anaemia, 
thrombocytopenia and a raised ESR. The difficulty arises in distinguishing 
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raised LFT due to drugs like methotrexate and NSAIDS to LFT raise due to the 
disease per se. Around 65% of the patients with Felty’s syndrome present with 
hepatomegaly.[52] 
6. Pulmonary involvement: 
 Pulmonary involvement is more commonly seen in males than in females 
with RA. Pleural involvement by the way of pleuritis is frequently seen though 
sometimes pleural effusions are also seen. Parenchymal pulmonary nodules are 
frequently seen in seropositive RA and are generally asymptomatic. In RA 
patients exposed to silica and coal dust, Caplan syndrome, which is pulmonary 
nodulosis and pneumoconiosis, is seen. Rheumatoid interstitial pulmonary 
fibrosis is found frequently found more in men with long standing, nodular, 
seropositive RA and in smokers.[53]Few cases of Bronchiolitis oblierans 
organising pneumonia has been documented in patients with RA and they 
generally tend to have a good prognosis. However obliterative constrictive 
bronchiolitis generally tends to have a poor prognosis.[53]Patient could have 
large airway obstructive disease which can be due to the primary disease or due 
to other risk factors. 
7. Cardiac involvement: 
  There are a number of cardiac presentations in RA and it is possibly due 
to various mechanisms like vasculitis, serositis, nodule formation, amyloidosis, 
valvulitis and fibrosis. The most common finding seen in cardiac patients with 
seropositive RA with nodules is pericarditis. Myocardial disease due to nodular 
29 
 
granulomatous disease is also seen in RA. There is also increased risk of 
ischemic heart disease and congestive heart failure.[54] 
8. Neurological involvement: 
 Patients with RA can present with mononeuritis multiplex or diffuse 
sensori-motor neuropathy caused by vessels neuropathy. Nerve compression 
due to peripheral entrapment neuropathy occurs and they correlate with the 
severity of local synovitis. The frequently involved nerves include are median, 
posterior tibial, ulnar and posterior interosseous branch of the radial nerve. 
Sometimes cervical neuropathy occur secondary to atlanto axial subluxation. 
9. Muscular involvement: 
 There can be muscular atrophy which occurs secondary to joint 
inflammation, medications, nutrition problems or neurological dysfunction. 
10. Renal involvement: 
 Rarely patients with RA have renal involvement in various forms like 
vasculitis, glomerulitis, membranous nephropathy or secondary reactive 
amyloidosis. Mesangio proliferative glomerulonephritis is considered as part of 
systemic organ involvement in RA. 
11. Amyloidosis:  
 Rarely long standing RA can be complicated by secondary amyloidosis. 
Few studies state that 0.7% patients of rheumatoid arthritis have clinical visceral 
amyloidosis.[47]The commonly involved organs in vasculitis include heart, liver, 
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kidney, spleen, skin and intestines. The most significant of these reactive organ 
manifestations is renal disease. 
12. Rheumatoid vasculitis: 
 RA is closely associated with small vessel vasculitis. Studies have 
demonstrated subclinical vasculitis in seropositive patients and immune deposits 
in affected skin and labial salivary glands.[55] HLA DRB1 alleles, mainly the B1 
0401 homozygotes have been seen to be associated frequently with vasculitis. 
Though it is a rare feature in RA, systemic vasculitis tend to indicate a poor 
prognosis.[47] Vasculitis generally involves the skin causing nail fold infarcts, 
gangrene of the digits and ulcers in the leg. 
13. Ocular manifestations: 
 Ocular manifestations are one of the most common extra articular 
manifestations seen in patients with RA and it occurs in about 25% of the 
patients.[56]These include dry eye (sicca), keratitis, keratolysis, episcleritis, 
scleritis among others. 
  
Variants of the disease: 
PALINDROMIC PATTERN:   
 Here the disease usually begins with pain in a single joint or periarticular 
tissue. Symptoms then worsen over a period of hours to few days and are 
associated with erythema and swelling. Symptoms then resolve in a reverse 
sequence leaving no residual deformities. Though they are not typically RA, 
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studies show that 85% of these patients progressed over a period of time to 
seropositive RA involving multiple joints.[57]It has now been found that use of 
antimalarials for this disease reduces the chances of progression to RA.[58] 
INSIDIOUS ONSET IN OLD INDIVIDUALS: 
  People who develop RA after 65 years of age frequently have stiffness, 
limb girdle pain along with diffuse swelling in the hands, wrists and forearms. 
Onset that mimics either polymyalgia rheumatica or remitting seronegative 
synovitis with pitting edema (RS3PE) can also be the presentation. Patients are 
less likely to have subcutaneous nodules or RF positivity at the onset of disease. 
This is despite the fact that RF is highly prevalent in the general population in 
this specific age group. Generally, these patients tend to have a more benign 
course when compared to younger people with RA. Though the onset is slow, 
stiffness is often incapacitating. As they tend to have associated osteoarthritis 
there is significantly greater scores for joint space narrowing and osteophytes at 
baseline when compared to younger RA patients.[59] 
Arthritis Robustus:  
Arthritis robustus is more of an unusual reaction in patients with RA than 
an unusual reaction of the disease.[60]  Usually patients are men whose have 
proliferative synovitis frequently with deformity, which causes little pain and  
disability. Patients are generally athletic and generally keep working. 
Periarticular osteopenia is rare, but new bone proliferation occurring at joint 
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margins near erosions of bones and cartilages are common. Bulky subcutaneous 
nodules and subchondral cysts can develop. 
 
3.7 ASSESSMENT OF SEVERITY OF THE DISEASE: 
In trying to sort out the relative roles of various disease manifestations, 
compared with various non-disease factors, to generate disability in RA, 
hypothetical models were proposed to predict disability in RA using socio-
cultural, demographic and clinical features of a cohort of RA patients.[61] 
Though their methods was not useful to explain the dynamics of disability in  
RA in 41% of cases, 33% was explained by disease related factors and 26% was 
explained by non-disease factors such as depression and psychological status. 
Various studies have discussed the following disease factors, which tend to 
correlate with a poor prognosis in patients with RA and a greater likelihood of 
severe joint involvement. 
1. Positive ACPA in serum 
2. Positive RF in serum[62] 
3. Elevated Health Assessment Questionnaire level of disability.[63] 
4. Rheumatoid nodules.[64] 
5. Depression.[65] 
6. Persistent ESR elevation (surrogate for disease control). 
7. Presence of a shared epitope (QKRAA) in the class II major 
histocompatibility genes. 
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HEALTH ASSESSMENT QUESTIONNAIRE 
 
 
 
ASSESSMENT OF DISEASE SEVERITY IN INDIVIDUAL PATIENTS 
 
Assessment of disease activity and its progression in a patient is very 
different from prognosis. Prognosis extrapolates and predicts an outcome from a 
known set of indices and the degree of measured activity of the disease. 
Assessment however, is the accurate evaluation of the disease at present in a 
patient or of the disease progression over a period of time. It was found that use 
of three or more assessment measures together provides us with a graph of 
progression of the disease in an individual that can be remedied by therapy.[66] 
For most patients with RA, a self-report questionnaire based on degrees of 
difficulty in performing activities of daily living correlates well with other 
widely accepted severity indices. The limitation of this form is however there is 
a failure to detect clinical improvement in those patients with very small 
impairment in activities of daily living. However these are still used now as they 
are very convenient. In some patients, more comprehensive joint counts are 
needed especially when biologics, DMARDS or surgery is planned. The 
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Thompson index used a few joints and weights from each of these joints to 
reflect the joint surface area, giving us a measure of the “burden of 
synovitis.”[67]Radiological investigations are used to detect the severity and the 
problems of long standing RA. Various indices like erosions, joint swelling and 
fractures are used. The correct choice of imaging is important in assessment of 
the destructive lesions of RA. Though USG and MRI are used to detect early 
changes X Rays continue to the cost effective first line investigations and 
various severity scales use X Rays. 
CLINICAL SEVERITY SCALES: 
A major problem in RA is having valid reproducible measures of disease 
activity measurement for initial evaluation as well as for determining prognosis 
and remission and then routinely measuring and following those in a clinic. 
Unfortunately, there is no single specific examination finding or laboratory 
investigation that satisfactorily measures disease severity and activity. 
Many measures and various scales have been proposed over a period of time 
and all of these are composite measures that include information derived 
various features like some predetermined combination of joint examinations, 
physician and patient assessment of disease activity, patient function and 
morbidity and laboratory measures of inflammation  like erythrocyte 
sedimentation rate or C-reactive protein . The American College of 
Rheumatology (ACR) has recently endorsed a fixed list of disease activity 
scales and measures that have been found to correlate with outcomes. The table 
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below gives a partial list of some of the better known of these measures. There 
is weakness and strengths in each of these scales.[68] Few of these tests rely only 
on data from the patients, while some have joint counts by the doctors  while 
others require laboratory investigations. As time for examination is less with 
many patients scales with lesser number of joints (DAS28), based fully on 
patient data(RAPID) or those which do not require investigations (Clinical 
Disease Activity Index) are more in vogue. There is a very high correlation 
among these measures, so currently it is more important that disease activity is 
measured and less important which of these measures are used. 
 
 
DAS28 SEVERITY SCALE 
The initial design of the DAS goes back to 1983. Initially at that time a 
modification of an existing disease activity index was used in small clinical 
trials.[69] DAS was first introduced by the Department of Rheumatology, 
University of Nijmegen In 1983 after assessing various data from their patients 
and determining the prognostic indicators among them. As a golden standard for 
disease activity was lacking at that time, patients were divided as having high or 
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low disease activity depending on the joint decision of the clinician and the 
patient. After that it was investigated which variables among the many, and in 
particular which combination of variables discriminated best between these two 
different disease states. This resulted in the Disease Activity Score (DAS) 
which was released in 1983.[70,71]The initial DAS included 44 swollen joints 
count, the Ritchie articular index, the Erythrocyte Sedimentation Rate and a 
general health assessment  based on a Visual Analog Scale. After further 
validation of the new 28 non-graded joint count for both tenderness and 
swelling, DAS28 was formed.[72]The results of both the DAS and the 
DAS28 have been found to not be directly interchangeable as in the DAS there 
is a range  which varies from 1 to 9 and in the DAS28 the range is from 2 to 10. 
So a transformation formula has been given by which we can calculate the 
DAS28 from the DAS value: DAS28= (1.072 x DAS) + 0.938.[73]Most studies 
show that serial measurements of the DAS28 is a strong predictors of physical 
disability and morbidity.[74] However differences do exist about whether they 
are predictors for radiological progression with some studies showing a positive 
correlation and some showing negative correlation.[75,76] However the present 
thought is that clinical severity scales shows the active inflammation and 
morbidity and does not correspond well with the chronic erosive process.[8] 
Based on the DAS scales, response criteria have been developed to determine if 
patient is responding to treatment: the EULAR response criteria. The EULAR 
response criteria include both changes in disease activity and current disease 
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activity.[77,78]To be designated as responders, patients should have a significant 
change in DAS scores and also low current disease activity. Three categories 
are defined: good, moderate, and non-responders. A cut-off level of the DAS of 
1.6 or a DAS28 of 2.6 corresponded with the patient being in remission after 
treatment.[79] 
COMPONENTS OF DAS28[80] 
1. The number of tender joints of the 28 joints that are measured (tender28) 
2.  The number of swollen joints of the 28 joints that are measured 
(swollen28) 
3.  The Erythrocyte Sedimentation Rate (ESR) given in mm/hour 
4. The patients’ general health (GH) score or global disease activity value 
measured on a Visual Analogue Scale (VAS) of 0 to 100 mm. 
Swelling of joints (SJC): 
Soft tissue swelling, detectable along the joint margin is considered. 
Synovial effusion generally means the joint is swollen. Bony swelling , 
deformities and oedema surrounding the joints do not constitute joint 
swelling.Fluctuation is generally a characteristic feature of swollen joints. 
Joint swelling can influence the range of joint movement (for eg: decreased 
dorsiflexion of the wrist, or decreased elbow extension). This can be used in  
determining the presence of swelling. [81] 
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Tenderness (TJC) of joints: 
Pain in a joint under defined circumstances which are  
1. Pain at rest with pressure (seen in MCP and wrist joints) 
2. Pain on movement ( shoulders) 
3. From questioning about joint pain  
The DAS28 can be calculated using the following formula [82]: 
DAS28=0.56*√(tender joints) + 0.28*√(swollen joints) +0.70*Ln(ESR/CRP) 
+ 0.014*VAS 
This calculation might not be easy, but there are various calculators 
which provide the value immediately. Based on these values patients can be 
classified into 3. 
1. DAS28 SCORE <3.2 – LOW DISEASE ACTIVITY 
2. DAS28 SCORE 3.2-5.1 – MODERATE DISEASE ACTIVITY 
3. DAS28 SCORE >5.1 – SEVERE DISEASE ACTIVITY 
The EULAR Response criterion is shown below. 
  A decrease in DAS28 score of 0.6 or less is generally considered to show 
a poor response, while decreases that are greater than 1.2 points indicate a 
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moderate or good response, but it is dependent on whether an individual's 
DAS28 score at the end point is above or below 3.2 respectively.[83,84] 
DAS28 improvement 
→
> 1.2 > 0.6  and  ≤ 1.2 ≤ 0.6 
Present DAS28↓ 
≤ 3.2 good response moderate response no response 
> 3.2 and ≤ 5.1 moderate response moderate response no response 
> 5.1 moderate response no response no response 
  
                    
RADIOLOGICAL SCALES 
Evaluation and interpretation of structural joint damage on repeated 
radiography is one of the central outcome measures in patients with rheumatoid 
arthritis, both in clinical trials and routine clinical management.[85,86] Generally 
radiological investigations give a permanent as well as comparative measure of 
damage in rheumatoid arthritis. X Rays of hands and feet have always been an 
important and fundamental part in the evaluation of RA course and its response 
to medication over the last sixty years.[87] The long-term severity and problems 
of RA was seen in longitudinal studies of various clinical cohorts that showed 
that the disease has continuous radiographic progression when seen in follow-
ups over 20 years and more.[88,89] The efficacy of  various DMARDs has been 
traditionally viewed by their effect in slowing down or reversing radiological 
40 
 
damages.[90] Also milder  radiographic progression of RA present, compared to 
previous times shows the improved outcomes of RA due to newer modes of 
treatment.[91,92]Recent advances in the field of radiology has resulted in newer 
methods of investigations like USG and MRI. These investigations are 
definitely valuable and have been found to be more sensitive than radiographs 
in finding early structural changes in joints and other structures. However, the 
availability of these, especially in the developed countries along with the high 
costs limits the use of these investigations in daily clinical practice. Therefore 
clinical trials tend to mainly rely on radiographs rather than other imaging 
technology.[93] Earlier radiographs were scored by the Steinbrocker scoring 
system9 which has a global damage score to both hands and wrists on a four-
point scale starting from I (minimal damage) to IV (severe damage).[94]The 
grade was measured by the worst change in any joint and so the score was 
biased toward the most affected joint. The Kellgren method, which was similar 
to the previously mentioned Steinbrocker method: a global grade was there as 
the addition of abnormalities of all the joints in both the hands and wrists.[95] 
The two most commonly used measures of radiographs now are that of Sharp[96] 
and Larsen.[97,98] These scales provide a continuous quantitative scale that 
extends for more than 100 units unlike other scales that give just qualitative 
assessment of the changes. The Sharp method consists of separate scores for 
both erosions and joint space narrowing and the Larsen method gives a global 
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score for each involved joint. Among all these scales because of the better 
ability of the Van der Heijde modification of the Sharp method [99] in detecting 
changes that occur over time in RA, at present this is most often used in clinical 
trials.[100] 
The Sharp Method and Van der Heijde modification of Sharp method 
The Sharp method initially consisted of radiographs of both hands and 
wrists and took into account several features like periosteal reaction, 
osteoporosis, cortical thinning, osteophytes formation, sclerosis, cystic changes, 
ankylosis, surface erosions and joint space narrowing.[96] Later due to various 
reasons, five of these were omitted from the final score. 
• Periosteal reaction was considered too unusual. 
• The quality of radiographs obtained was generally too poor to find 
cortical thinning.  
•  Osteoporosis, osteophyte forrmation and sclerosis are now considered to 
be secondary changes. 
The final Sharp method of scoring, thus includes just two scores, one 
for erosions and one for joint space narrowing.[101]In the original Sharp method, 
erosion scores were between 0 to 5 and a number between these was given to 
each joint that was taken based on the number of erosions. “5” denoted total 
joint destruction.  
Joint space narrowing is scored from 0 to 4 as follows [102]: 
0 - Normal 
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1 - Focal narrowing 
2 - Reduction of less than 50% of total joint space 
3 - Reduction of greater than 50% of total joint space 
4 - Ankylosis 
The total number and selection of the joints in the Sharp score changed from 
including hands and wrists to hands (including wrists) and feet. In the Van der 
Heijde modification of the Sharp score, 16 joints from each hand and wrist was 
included in the erosion score. For the feet, each side of the 10 MTP joints and 
the 2 interphalangeal joints of the big joints alone are evaluated.[103] 
 The Van der Heijde modification of Sharp defines erosions as[104]: 
• 0 – Normal (no features) 
• 1 - Discrete erosions seen 
• 2 to 3 - Larger erosions present. It is further graded as 2 or 3 depending 
on the surface area involved. 
• 4 - Erosions extend over the middle of the bone. 
• 5 - Complete collapse of the involved joint. 
Van der Heijde score for joint space narrowing includes 15 places from the 
hands with wrists and six areas from both the feet. Joint space narrowing is 
generally scored similar to the original definition given by Sharp, as shown 
above. The maximum erosion score obtainable is 160 for hands with wrists and 
120 for feet. Similarly the maximum joint space narrowing score for the hands 
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is 120 and 48 for feet. So the total van der Heijde radiographic score is from 0 
to 448.[103] 
 
3.8 ANTIBODIES IN RA 
Autoantibodies are proven to be very useful tools in the diagnosis and 
prediction of the various autoimmune rheumatic diseases. Emerging recent data 
about various autoimmune connective tissue disorders have shown that clinical 
evolution of the disease from a preclinical phase to a clinical disease is 
generally marked by changes in the immune response, with autoantibodies 
formed which are directed against different antigenic targets at various disease 
phases.[105] Although many of these diseases have traditionally been 
characterised by highly phenotype-specific autoantibodies like anti dsDNA in 
systemic lupus erythematosus and anti-topoisomerase-1 antibodies in diffuse 
scleroderma, the discovery of  specific autoantibody for RA lagged behind. 
However there has been rapid progress recently after citrullinated proteins were 
found to be specific targets for autoantibodies in RA. The two main set of 
antibodies at present are rheumatoid factors (RFs) and anticitrullinated protein 
autoantibodies (ACPAs). Out of these the more commonly available and used is 
the Rheumatoid Factor, which is also used in this study.  
RHEUMATOID FACTOR 
Initially the Rose-Waaler agglutination test was introduced which first 
suggested the presence of autoantibodies in rheumatoid arthritis in the early 
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1940s.[106] At that time serum was taken from patients with RA it was found to 
cause agglutination of blood cells of sheep, which previously had been 
sensitized by subagglutinating doses of rabbit’s anti-sheep erythrocyte 
antibodies.[107] Later it was shown that the assays were actually detecting 
immunoglobulin M (IgM) antibodies in patients with RA against the Fc portion 
in IgG.[108] Further improvements resulted in RF assays in various methods 
which were more convenient but had the equivalent sensitivity and specificity 
like radioimmunoassay, ELISA and nephelometry methods. RF positivity is 
also seen in 1% in younger individuals moving up to 5% in individuals who are 
older than 70 years and also in patients with diseases other than RA, like 
Sjögren’s syndrome, cryoglobulinemia and chronic infections.[109,110] Detection 
of  IgA and IgG RFs along with evidence of somatic hypermutation have 
provided the thought that some RFs in rheumatoid arthritis are T cell 
dependent.[111,112] There are differences over the uses of measuring all three RFs 
compared to one. There are some studies which suggest that measuring all 3 
RFs increase the specificity.[113] However a recent study has showed that 
measuring of all 3 assays do not improve the sensitivity and specificity when 
compared to single assays.[114] There are a few studies which determine 
differences between the various types of RF. Some state that IgM RF helps in 
predicting development of RA while some studies states that IgG RF correlates 
with radiological progression though other studies seem to differ.[115] IgM RF 
remains the most sensitive antibody. Also early onset of RF positivity in 
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patients with rheumatoid arthritis is found to be correlating with increased 
severity of the disease probably due to the role of the antibodies in 
amplification.[116]  
3.9 DIAGNOSIS 
 There is no single test to confirm the presence of RA. A patient is 
diagnosed as having RA based on a multitude of factors like relevant history, 
supportive clinical features and supporting immunological investigations along 
with exclusion of other similar diseases. For the sake of uniformity all over the 
world and for the sake of clinical studies American College of Rheumatology 
criteria for RA was published in 1987. Though it was not used for individual 
cases for treatment, the requirement of synovitis needing to be greater than 6 
weeks helped in eliminating a number of patients who had transient synovitis. 
This ACR classification was again revised in 2010 by the EULAR (European 
League Against Rheumatism) and ACR.[117] The major differences were that the 
newer classification stressed on earlier diagnosis and hence more importance 
was given to serology and less to the type of clinical presentation. It also 
considered the newer modes of radiological investigations like USG and MRI 
which was not considered in the previous criterion. As it a new criterion, the 
long term efficacy of this criterion is not yet known and is the topic of various 
studies all over the world. 
 
46 
 
 
 
47 
 
          ACR/EULAR CRITERIA FOR RA ( POSITIVE- 6 OR MORE) 
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4. MATERIALS AND METHODS: 
4.1 INCLUSION CRITERIA: 
 A total of 100 patients who attended the outpatient clinic of the 
Department of Rheumatology in Government Kilpauk Medical College and 
Hospital were consecutively selected for the present study during the period of 
December 2011 – June 2013. The patients who were selected for the study was 
diagnosed to have rheumatoid arthritis based on the 2010 ACR/EULAR Criteria 
for diagnosing RA. These patients had 6 or more points in the criteria. 
4.2 EXCLUSION CRITERIA: 
1. Collecting a proper history has been the most important part of the study. As 
presence of the disease in the patient as well as treatment taken during the 
period tends to affect both the clinical severity scales as well as the progression 
of radiological persons, patients with previously diagnosed RA, whether on 
proper follow up or not, were omitted from the study. 
2. Patients with history as well as clinical features of other diseases which 
affected the joints were also excluded from the study as it would be difficult to 
differentiate if the signs were due to RA or any other concomitant disease. This 
included diseases like osteoarthritis, post viral arthlagia, gout and 
hypothyroidism. 
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3. Patients with presence of features or antibodies suggestive of autoimmune 
connective tissue disorders other than rheumatoid arthritis were also excluded 
from the study as the cross positivity of various antigens need to be taken into 
account. 
 With the above given inclusion and exclusion criteria, patients suffering 
exclusively from rheumatoid arthritis were included in the study. 
4.3 DATA COLLECTION 
 First the entire details of the study were described to each individual 
patient. Their role in the study was fully explained and their willingness to 
participate in the study obtained along with a written consent. 
4.3.1 History: An exhaustive and detailed history was obtained from the patient. 
This included history of their various symptoms pertaining to RA and also other 
unrelated symptoms. All significant past histories and treatment histories were 
also noted. 
4.3.2 Clinical examination: In a well lit room patient was examined in full 
detail. All relevant clinical finding were noted. The individual joints were 
examined and patients were also examined for extra-articular manifestations. 
The joint count for swelling and tenderness of joints were done to calculate the 
DAS28 score. Each patient’s counts were entered into a proforma and the 
individual scores calculated. 
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DAS28 form 
 
Patient name     …………………………………………….  Date of Birth   ____-____-______  
 
Observer name   …………………………………………… Date  ____-____-______ 
 
 Left  Right  
 Swollen Tender Swollen Tender 
Shoulder     
Elbow     
Wrist     
MCP 1     
 2     
 3     
 4     
 5     
PIP 1     
 2     
 3     
 4     
 5     
Knee     
Subtotal     
Total Swollen  Tender  
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How active was your arthritis during the past week? 
(Please mark the degree of activity on the scale below by placing a vertical line | ) 
 
 
 
      
 
 
Swollen Joint Count (0-28)  
Tender Joint Count (0-28)  
ESR  
VAS disease activity (0-100mm)  
  
DAS28 = 0.56*√(t28) + 0.28*√(sw28) + 0.70*Ln(ESR) + 0.014*VAS  
  
            The above mentioned form was obtained from www.das28.nl, which is 
the official website for DAS28 and the same is used in many clinical trials. 
Using the calculator given in the same aforementioned website, the individual 
scores were calculated for each patient and they were divided into 3 categories 
based on the scores 
Score  < 3.2            Low disease activity 
Score  3.2 -5.2        Medium disease activity 
Score  > 5.2            High disease activity 
Not active at all Extremely active 
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4.3.3 RADIOLOGICAL EXAMINATION: The patients were then taken to the 
Department of Radiology for radiographs of their hands and feet. Positioning of 
the hands and feet were well standardised with the same technician being used 
for all the patients. The x-ray tube was positioned 100 cms from the cassette and 
the beam was centered on the 3rd metacarpal for the hands and the 3rd MTP joint 
for the feet.  
For the hands, the elbows were in the same plane as the hands and the 3rd 
metacarpal was in line with the forearm and the fingers were placed flat on the 
table.  
For the foot, patient was told to apply pressure of the entire foot on the 
table so that the foot is completely flat. The emphasis was laid more on the toes, 
particularly the MTP joints as the score involves these joints. 
The various radiographs were studied by the Professor and HOD, 
Department of Radiology, Government Kilpauk Medical College and Hospital 
along with the primary observer and the individual scores for each patient was 
obtained based on the Van der Heijde modification of Sharp score. This took 
into account the erosions and the joint narrowing in various defined joints. Each 
patient’s finding was denoted in the following score sheet and the total score 
obtained by the sum of 2 scores. 
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                 Radiographs of patients involved in the study  
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Though there is no proper classification based on the scores, the patients were 
divided based on the scores into 5. 
Group 1 - patients with score of O 
Group 2 - patients with a score of 1 to 6 
Group 3 - patients with a score of 7 to 12 
Group 4 - patients with a score of 13-20 
Group 5 - patients with a score of   > 20 
4.3.4 BLOOD INVESTIGATIONS 
 All the patients underwent the regular blood investigations required for 
diagnosing and managing RA. This included ESR, CRP, IgM RF , anti CCP , 
renal function and liver function tests among others. The IgM RF positivity and 
negativity was checked for all the patients. Also, using aseptic precautions, 2ml 
of blood was withdrawn from a venupuncture site from all these patients. The 
blood was then centrifuged and the serum separated and stored in special 
containers in a freezer at -20 degrees Celsius. After all the samples were 
collected the serum was used to detect the IgG RF among the various patients 
by the ELISA reader in the Department of Rheumatology, Government Kilpauk 
Medical College. The patients with positive and negative IgG RF were noted.  
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                    IgG RF ELISA done is serum of patients of the study. 
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4.4 STATISTICAL ANALYSIS 
 STATISTICAL TOOLS: 
The information collected regarding all the selected cases were then recorded in 
a Master Chart. Data analysis was done with the help of computer using 
statistics software (SPSS). 
Using this software range, frequencies, percentages, means, standard 
deviations, chi square and 'p' values were calculated. Kruskul Wallis chi-
squaretest was used to test the significance of difference between quantitative 
variables and Yate’s test for qualitative variables. A 'p' valueless than 0.05 is 
taken to denote significant relationship. 
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5. OBSERVATIONS AND ANALYSIS 
 A total number of 100 cases satisfying the criteria for diagnosis of RA 
were taken. The age and sex distribution of these patients have been illustrated 
in table 5.1 
Table 5.1 : Age and sex distribution of RA patients in the present study.  
AGE (YEARS) No. of patients (n=100) Sex ( M: F) 
0-20 2 2:0 
21-30 8 3:5 
31-40 24 8:16 
41-50 35 7:28 
51-60 21 3:18 
>60 10 1:9 
 
 Out of the 100 cases taken for the study, there were 24 males and 76 
females. This corresponded to a Male : Female ratio of 1:3.This correlates with  
various studies which shows a female preponderance of RA. This is illustrated 
in chart 5.1a.  
 The maximum cases were in the age range of 41-50 followed by the age 
group of 31-40 and 51-60. This correlates with various studies which show that 
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RA is mostly a middle age disease. The age distribution in males and females 
are illustrated in charts 5.1b and 5.1c. 
Chart 5.1a Gender distribution of the patients. 
 
Chart 5.1b Age distribution in the Male patients. 
 
Males
24%
Females
76%
Gender distribution in the study
8%
13%
33%
29%
13%
4%
No. of male patients in various age groups
0-20 21-30 31-40 41-50 51-60 >60
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5.1c Age distribution of female patients in the study
 
 
The average age of the patients in the study was seen 45.9 years and the 
median was 45 years. This correlates with the fact that RA is a disease of the 
middle age. Moreover various studies suggest that long time complications tend 
to increase with duration of the disease. RA tends to increase risk for other 
disease like atherosclerosis and this is even more significant as elderly people 
already have an increased risk for most of these diseases. The gender 
distribution again correlates with the general literature about RA. Almost all 
connective tissue disorders tend to occur more in females compared to males.  
0%
6%
21%
37%
24%
12%
No. of female patients in various age groups
0-20 21-30 31-40 41-50 51-60 >60
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All the patients were taken as suffering from RA based on the 
ACR/EULAR score. The distribution of the score in the 100 patients was 
observed and the distribution is shown in table 5.2 and chart 5.2 
Table 5.2:  Distribution of ACR/EULAR Score in RA patients in the study. 
ACR SCORE No. of patients 
6 12 
7 44 
8 28 
9 13 
10 3 
 
Chart 5.2: Distribution of ACR/EULAR Score in RA patients in the study.
 
The most common score seen in the patients in the study was 7 followed by 8. 
The least score seen was 10. 
0 10 20 30 40 50
6
7
8
9
10
ACR/EULAR Score in  patients in the study
ACR/EULAR Score in  patients 
in the study
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Table 5.3:  Distribution of the cases based on DAS28 scores.   
DAS28 SCORE No.of patients 
Mild disease activity ( <3.1) 19 
Medium disease activity (3.2-5.1) 49 
High disease activity ( >5.1) 32 
 
Chart 5.3: Distribution of the cases based on DAS28 scores.   
 
  
The majority of the cases in the study came under the medium disease 
activity group (49%). This was followed by the patients in the high disease 
activity (32%) and then the low disease activity in the group (19%).  
19%
49%
32%
Distribution of cases based on DAS28 scores
Mild disease activity ( <3.1)
Medium disease activity (3.2-
5.1)
High disease activity ( >5.1)
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Table 5.4: Distribution of Modified Sharp score in the patients of the study 
Modified Sharp Score No. of patients 
0 50 
1-6 20 
7-12 8 
13-20 3 
>20 19 
 
 On examining the radiographs it was found that most common modified 
Sharp score was 0. This was followed by the range of 1-6 and then > 20. 
Chart 5.4a: Distribution of Modified Sharp score in the patients of the study 
 
 
54%
22%
0%
3%
21%
Distribution of patients based on Sharp score
0 1-6 7-12 13-20 >20
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 There are two components of modified Sharp score. One is erosions score 
and the second one is joint space narrowing. 
Chart 5.4b Patients in the study with erosions in X Rays. 
 
Chart 5.4c Patients with joint space narrowing in X Rays. 
 
38% of our patients had erosions and 47% had joint space narrowing in their                     
X Rays. 
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Table 5.5 IgM and IgG RF positivity in the patients in the study. 
Rheumatoid Factor POSITIVITY NEGATIVITY 
IgM RF 49 51 
IgG RF 31 69 
Chart 5.5a IgM RF positivity in the patients in the study. 
 
Chart 5.5b IgG RF positivity in the patients in the study.
 
 
IgM RF in patients of the study
Positive
Negative
IgG RF positve patients in the 
study
Positive
Negative
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Correlation between various variables 
Table:5.6: Correlation of Age distribution with IgM RF 
IgM RF AGE IN YEARS p= 0.852 
<20 20-29 30-39 40-49 50-59 >60 
Positive 1 2 11 19 11 5 
Negative 1 2 12 16 10 10 
  
1. In the study, when the age distribution was compared with IgM positivity, it 
was found out that there was no significant relationship between any age group 
and IgM positivity. IgM RF tended to be distributed equally in all various age 
groups. This is illustrated in the chart 5.6  
Chart 5.6: Correlation between age and IgM RF 
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2. Similarly the relationship between various age groups and IgG positivity was 
also studied as part of the study. The results are put in table 5.7 and chart 5.7. 
Table 5.7 : Correlation of age and IgG RF 
 IgG RF AGE IN YEARS p=0.107 
<20 20-29 30-39 40-49 50-59 60-69 
Positive 0 1 3 16 5 6 
Negative 2 3 20 19 16 9 
 
            Chart 5.7: Correlation between age and IgG RF positivity 
 
It was found out that IgG positivity also did not have any significant 
correlation with any specific age group and tended to equally distributed all 
over the age spectra.                  
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3. The DAS28 scores of various patients were also compared with their 
respective ages. The results are shown in table 5.8 and chart 5.8. 
TABLE 5.8 : Correlation between Age and DAS28 
AGE 
(YEARS) 
DAS28 SCORE p=0.537 
<3.2 3.2-5.1 >5.1 
<20 1 1 0 
20-29 0 2 2 
 30-39 8 8 7 
40-49 6 18 11 
50-59 2 11 8 
>60 2 9 4 
 
Chart 5.8 : correlation between age and DAS28 
 
  
It was found out that the DAS28 scores did not correlate to any specific 
age group differences and the various scores were distributed along the entire 
age spectrum. 
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4. The results of comparison of various modified Sharp scores with the age of 
the patients are given in table 5.9 and chart 5.9 
Table 5.9: Correlation between age (years) and Sharp scores 
AGE 
(YEARS) 
Sharp score p=0.986 
0 1-6 7-12 13-20 >20 
<20 2 0 0 0 0 
20-29 2 1 0 0 1 
30-39 13 5 1 1 3 
40-49 17 7 2 1 8 
50-59 11 3 3 1 3 
>60 5 4 2 0 4 
 
Chart 5.9 : Correlation between age (years) and Sharp scores 
 
  
It was found that there was no significant association of modified Sharp 
score with age distribution- that is patients had erosions and joint space 
narrowing irrespective of their age. 
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5. Correlation between gender and IgM RF score 
 The gender of the patients and their IgM RF scores were compared. The 
results are given in table 5.10 and chart 5.10 
Table 5.10 : Correlation between sex distribution and IgM RF 
SEX 
DISTRIBUTION 
IgM RF P=0.548 
Positive Negative 
Males 12 12 
Females 37 39 
                                                                                                                                            
Chart 5.10: Correlation between sex distribution and IgM RF 
 
 The gender of the patients and their IgM RF positivity and negativity 
studied. The variables were not found to be significantly associated with a p 
value of 0.548. So IgM RF occurs in patients irrespective of whether they are 
males or females. 
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 6. Similar to IgM RF, IgG RF positivity was also studied corresponding to the 
gender of these patient and its results are given in table 5.11 and chart 5.11. 
Table 5.11: Gender correlation with IgG RF 
SEX 
DISTRIBUTION 
IgG RF P<0.322 
POSITIVE NEGATIVE 
Males 6 18 
Females 25 51 
 
Chart 5.11: Gender correlation with IgG RF 
 
 The p value of 0.322 showed that there was no significant association of 
gender with IgG RF. IgG RF positivity occurred in patients irrespective of them 
being males or females. Thus it was found that both the antibodies had no 
significant correlation with the gender of their patients  
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7. The individual DAS28 scores of all the patients were next studied with the 
gender of the patients and the result of the study is given in table 5.12 and chart 
5.12 that are shown below 
Table 5.12: Gender correlation with DAS28 
SEX 
 
DAS28 TOTAL 
 
pVALUE 
 
0.962 
<3.2 3.2-5.1 >5.1 
Male 
 
6 
 
10 
 
8 
 
24 
 
Female 13 39 24 76 
 
Chart 5.12: Gender correlation with DAS28 
 
 
 It was found that the DAS28 scores had no significant association with 
the gender of the patient and was distributed in both males and females. 
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8. The individual modified Sharp’s scores of all the patients were taken and the 
gender distribution for the various ranges of the score was studied. The results 
are given in chart 5.13 and table 5.13 
Table 5.13 Gender correlation with Sharp score 
GENDER 
 
SHARP SCORE TOTAL 
 
pValue 
1.930 0 1-6 7-12 13-20 >20 
MALE 
 
 
13 
 
 
6 
 
1 
 
1 
 
3 
 
24 
 
 
FEMALE 
37 
 
14 
 
7 
 
2 
 
16 
 
76 
 
 
Chart 5.13: Gender correlation with Sharp score 
 
 The modified Sharp score did not have any significant correlation to the 
gender of the patients and erosions and joint space narrowing occurred 
irrespective of the patient being male or female. 
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9. The result of the comparison of the ACR score with IgG RF is given in table 
5.14 and chart 5.14. 
Table 5.14: Correlation of ACR/EULAR score with IgG RF. 
ACR IgG Positive IgG Negative  
 
P=3.773 
6 3 9 
7 14 30 
8 10 18 
9 2 11 
10 2 1 
 
Chart 5.14: Correlation of ACR/EULAR score with IgG RF. 
 
 It was found that there was no significant correlation between the two 
variables. Hence higher ACR score did not indicate increased presence of IgG 
RF. Comparison with IgM RF was not done as IgM RF was a component of the 
score.  
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10. Similarly the ACR/EULAR score was correlated with DAS28 and the 
results are given in table 5.15 and chart 5.15. 
Table 5.15: Correlation between ACR score and DAS28 
ACR <3.2 3.2-5.1 >5.1 Total No. 
6 4 6 2 12 
7 7 26 11 44 
8 6 12 10 28 
9 2 5 6 13 
10 0 0 3 3 
 
Chart 5.15: Correlation between ACR score and DAS28 
 
              There was no significant correlation between the various ACR scores 
and DAS28 scores. The higher ACR scores did not correspond to higher DAS28 
scores or vice versa. 
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11. The ACR/EULAR scores was then compared to the modified Sharp’s score 
of the patients and the results are given in table 5.16 and chart 5.16. 
Table  5.16: Correlation between ACR score and Sharp score 
ACR 
SCORE 
Modified Sharp Score  
 
p=0.154 
0 1-6 7-12 13-20 >20 
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Chart 5.16: Correlation between ACR score and Sharp score 
 
 There was no significant correlation between the two. The higher 
ACR/EULAR scores did not correlate to higher modified Sharp scores or vice 
versa. 
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12. Correlation between DAS28 and modified Sharp score. 
 The first part of the study is to study the relationship of the clinical 
severity scale ( DAS28 ) and compare it with the Van der Heijde modification 
of Sharp score which gives us the erosions and radiographic severity in the 
patients. Both the scores were calculated for the 100 patients and recorded. 
These scores were then compared to determine if the severity tends to correlate 
in both the scales. The results of the correlation is given in table 5.17 and 
chapter 5.17 
Table 5.17: CORRELATION BETWEEN DAS28 AND SHARP SCORE 
SHARP 
SCORE 
DAS28 SCORE  
 
 
 
 
 
P = 0.069 
<3.2 3.2-5.1 > 5.1 
0 15 21 14 
1-6 3 7 10 
7-13 0 5 3 
13-20 0 2 1 
>20 1 14 4 
 
 The p value of 0.069 shows that though there is an apparent correlation 
between the two scales there is no statistically significant correlation. The 
erosions and joint narrowing which categorise worsening of bone changes of a 
patient tend to occur irrespective of the DAS28 score of the patients 
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Chart 5.17: CORRELATION BETWEEN DAS28 AND MODIFIED SHARP 
SCORE 
 
 The p value of 0.069 shows that there is no significant correlation 
between the DAS28 score and the modified Sharp score of the individual 
cases. Patients with an increased radiograph changes did not actually have 
higher scores in DAS28. Hence though both the scales are commonly used to 
detect the severity of the disease , it seems that they depict severity in two 
different parts of the disease. The DAS28 gives an idea of the acute 
inflammation and synovitis which cripples the patient while the Sharp’s score 
seems to provide us with information of the bone changes which occur in these 
patients over a period of time and the long term morbidity associated with these 
changes. Scoring one scale does not help us to predict the scores in the other 
scale. 
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13. The DAS28 scores were also compared with IgG RF to determine whether 
there was any significant correlation and its results are given in table 5.18 and 
chart 5.18 
Table 5.18: Correlation of DAS28 with IgG RF 
DAS28 SCORE IgG RF  
 
P=5.109 
 
POSITIVE NEGATIVE 
<3.2 2 17 
3.2-5.1 19 30 
>5.1 10 22 
 
Chart 5.18: : Correlation of DAS28 with IgG RF 
 
 It was found that IgG RF positivity did not correspond to higher severity 
scores by DAS28. Similarly IgG RF negativity did not correspond to lower 
scores in DAS28. 
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14.  To determine if bony changes in RA could be predicted by immunological 
tests the modified Sharp score of the patients were tested with both IgM RF and 
IgG RF positivity. The result of the correlation between IgM positivity and 
Sharp score is given in chart 5.19 and table 5.19 
Table 5.19: Correlation between Sharp score and IgM RF 
SHARP 
SCORE 
IgM RF TOTAL  
 
p=1.126 
POSITIVITY NEGATIVITY 
O 26 24 50 
1-6 9 11 20 
7-12 3 5 8 
13-20 1 2 3 
>20 10 9 19 
 
Chart 5.19: Correlation between Sharp score and IgM RF 
 
 It was found there was no significant correlation of IgM RF with 
increased erosions and joint space narrowing in radiographs. IgM RF positivity 
did not correspond to increases bony changes. 
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15. Similarly IgG RF positivity and the Sharp scores of the various patients of 
the study were compared.  The result of the correlation is given in chart 5.20 
and table 5.20. 
Table 5.20: Correlation between Sharp score and IgG RF 
SHARP 
SCORE 
IgGRF TOTAL 
SCORE 
 
 
 
 
 
p < 0.001 
POSITIVE NEGATIVE 
0 3 47 50 
1-6 8 12 20 
7-12 5 3 8 
13-20 2 1 3 
>20 13 6 19 
 
Chart 5.20: Correlation between Sharp score and IgG RF 
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 The p value was 0.000 which is noted as less than 0.001. Hence there 
was a significant correlation between IgG RF positivity of the patients and 
the bony changes in the radiographs of these patients. Patients who had 
IgG RF positivity tend to progress to increased bony changes which are 
detected by radiographs. 
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6. DISCUSSION: 
This study was based on the data collected from 100 patients who had 
been diagnosed as suffering from Rheumatoid arthritis according to the 
ACR/EULAR CRITERIA FOR RA.[117] The various data collected included 
age, sex, ACR/EULAR score, IgM RF, IgG RF, DAS28 score and Van der 
Heijde modification of Sharp score. 
The first part of the study was to determine if the 2 types of severity 
grading – the clinical and the radiological, were comparable.  
The DAS28 scores were calculated for all the patients. The mean score 
was 4.54 with a standard deviation of 1.03. The median score value was 4.6 
and mode was 3.15. 
Similarly the Van der Heijde modification of the Sharp score was 
calculated for all the individual patients and divided into 5 groups. Because of 
the present changes only in a part of the people with most others having a score 
of 0, the mean was 10.49 with a standard deviation of 22.6. 
 It was found that though those patients with greater Sharp score tended 
to have higher DAS28 scores it was not significant when determined by 
statistics. This showed that 2 scales are not interchangeable. Similar results 
are also seen in other studies done in many parts of the world which showed 
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that the 2 most commonly used methods to detect severity of RA (clinical and 
radiographs) are actually independent of each other.[7,76,118,119] Hence the latest 
thought based on various books and studies is that in RA, inflammatory 
synovitis, represented by the DAS28 and proliferative synovitis which causes 
erosions and other bony changes and is represented by the modified Sharp score 
are not the same but actually they reflect two different aspects of the same 
disease.[8] This is especially important due to the following reasons. 
 Most of the various DMARDs are investigated based on their efficacy 
using one of the 2 scales and hence it is important to realise that 
DMARDs effective in reducing the acute inflammation and morbidity 
might not be effective in reducing the progression in bony changes and 
vice versa. 
 Though radiological progression of the disease is very important in 
preventing long term morbidity, patients with RA generally are more 
distressed by the acute symptoms like swelling, tenderness and early 
morning stiffness which are best depicted by clinical scales like DAS28. 
So though it is important to look for progressions, DAS28 and other 
clinical scales remain the most important part of management of RA. 
 The fact these two scales represent two different pathologies probably 
means that the clinician should consider treatment against both the 
pathologies in order to treat the patient comprehensively. 
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The second part of the study was to determine if the there was any 
correlation between the DAS28 scores and IgG RF positivity. Out of the 100 
patients who were taken for the study IgG RF was positive in 31 of the patients 
and negative in 69 of the patients. The Sharp score of all the patients were 
compared. Our study showed that there was a significant correlation 
between IgG RF positivity and presence of bony changes seen in 
radiographs. The p value was less than 0.001(highly significant). 
This assumes importance, especially in the fact that in our study that though 
IgM RF was positive in many patients with presences of changes in 
radiographs, there was no significant correlation with a p value more than 0.05. 
Hence IgG RF can predict radiographical progression and hence can be used as 
a tool to determine and predict bony changes. This in turn can lead to early 
detection of patients vulnerable to erosions and other changes and hence more 
aggressive management in those patients. The finding of the study collaborated 
with similar studies done around the world which states that though IgM RF is 
most sensitive and is an important in predicting the clinical severity of the 
disease other antibodies IgG RF and anti CCP predict bony changes 
better.[115,120-122] 
The results from other data collected from the studies were also studied. The 
age of the patients in the study varied from 18 to 70 with the mean age being 
45.90 years with a standard deviation of 11.29 on both sides. The median age 
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was 45 years and the maximum patients with a single given age (given by 
mode) were 35. This age spectrum is similar to that seen in various other studies 
about RA which says most commonly disease occurs at 35-40 years of age.[18] It 
was also found that age of the patient did not correspond to different variables 
that determine the severity of the disease which were studied in the trial. 
Among the patients involved in the study the male:female ratio was 1:3 
which was similar to that present in other studies. There was no increased 
presence of disease severity in either of the gender. 
There was also no significant correlation between DAS28 and IgG RF, 
showing that though IgG RF was useful in predicting the radiological 
progression of the disease, it did not correlate with the clinical severity of the 
disease. 
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7. CONCLUSION 
• Though both DAS28 and Sharp score both help to determine the severity 
of the disease, they detect two different aspects of the same disease and 
are hence not changeable. 
• As patients symptoms and present morbidity are best determined by 
clinical severity scales, DAS28 and other severity scales remain the most 
important tool to determine the prognosis and plan management. 
• Sharp score and other radiological scale do not determine of the severity 
of the disease but detect bony changes that predict long term morbidity. 
•   Though IgM RF and anti CCP are most commonly used in RA, IgG RF 
predicts radiological changes like bony erosions and joint space 
narrowing and can hence be used to predict long term changes. 
• IgG RF positive patients can hence be treated more aggressively in view 
of their tendency to have bony changes later. 
• Newer modalities of investigations like USG and MRI were not taken 
into consideration. 
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8. LIMITATIONS OF THE STUDY 
1. Study population is small. 
2. The study population was consecutively selected. The number of 
seropositive patients and seronegative patients might not represent their 
distribution in the general population. 
3. Only the most commonly used 2 scales were chosen. Other similar scales 
were not studied. 
4. Long term progression of the disease and its influence on the scales was 
not studied 
5. Similarly the effect of treatment on these scales was not detected as 
patients who were newly diagnosed alone were included in the study. 
6. Anti CCP role to determine the severity of the disease and predicting the 
radiological changes is not studied and compared with IgG RF. 
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ABBREVIATIONS 
RA        - Rheumatoid Arthritis 
RF        -Rheumatoid Factor  
IgG       -Immunoglobulin 
EBV       -Ebstein Barr Virus 
CMV       -Cytomegalo Virus 
HLA       -Human Leucocyte Antigen 
IL1       -Interleukin 
DAS       -Disease Activity Scale 
TNF       -Tumor Necrosis Factor   
Anti CCP      -Anti citrullinated protein antibody 
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PROFORMA 
 
NAME:       
AGE:   
SEX: 
ADDRESS:       Rh. No.: 
RR. No.: 
       
HISTORY AND PAST HISTORY: 
 
 
DURATION OF ILLNESS: 
SIGNS: 
 GENERAL 
 Built:    Pallor:   Icterus: 
 Pedal oedema:  Fever:     Hydration: 
 Clubbing    PR:                               BP: 
          
CVS: 
RS : 
PER ABDOMEN: 
CNS: 
 
 
Blood: 
Complete haemogram - Hb. 
                                        TC   
                                        DC 
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                                        ESR 
                             PLATELETS 
              Blood – Sugar 
                                       Urea 
                              Creatinine 
    Serum electrolytes Sodium 
                               Potassium 
      Serum Rheumatoid factor 
      Serum C-Reactive protein 
 
Urine: 
                        Albumin   
                                       Sugar 
                                  Deposits. 
 
DAS 28 SCORE 
 
SHARP’S SCORE  
 
 
IgG RF 
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JOINT DISTRIBUTION (0-5) SCORE PATIENT’S 
SCORE 
1 large joint 0  
2-10 large joints 1  
1-3 small joints (large joints not 
counted) 
2  
4-10 small joints (large joints not 
counted) 
3  
>10 joints (at least one small joint) 5  
SEROLOGY (0-3)   
Negative RF AND negative ACPA 0  
Low positive RF OR low positive 
ACPA 
2  
High positive RF OR high positive 
ACPA 
3  
SYMPTOM DURATION (0-1)   
<6 weeks 0  
≥6 weeks 1  
ACUTE PHASE REACTANTS (0-1)   
Normal CRP AND normal ESR 0  
Abnormal CRP OR abnormal ESR 1  
TOTAL SCORE  
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 MASTER CHART 
NAME  AGE SEX  
OP 
No. 
ACR 
SCORE 
IgM 
RF DURATION ESR 
Tender 
Jts 
Swollen 
Jts DAS 28 
Xray 
erosion Jt. Narr 
Total 
Score IgG RF 
NARMADHA 40 F 763/12 10 POS 3 YEARS 50 22 27 7.94 100 59 159 POSITIVE 
KARPAGAM 56 F 298/12 8 NEG 1 YEAR 24 12 7 5.76 1 8 9 POSITIVE 
RAMAYEE 45 F 303/11 10 POS 2 YEARS 30 13 3 5.44 27 21 48 POSITIVE 
RAMESH 38 M 403/11 10 POS 5 YEARS 27 20 8 6.72 0 4 4 NEGATIVE 
RUKMANI 56 F 520/11 7 NEG 9 MONTHS 25 5 1 4.35 6 4 10 NEGATIVE 
KASIYAMMAL 50 F 101/12 7 NEG 2 YEARS 40 8 1 5.15 0 0 0 NEGATIVE 
DEVI 30 F 97/12 8 NEG 8 MONTHS 20 2 0 3.17 3 0 3 NEGATIVE 
KUMARI 45 F 790/11 9 POS 8 MONTHS 20 8 2 4.5 0 0 0 NEGATIVE 
SUGUNA 40 F 521/12 7 NEG 5 MONTHS 80 4 0 4.61 0 0 0 NEGATIVE 
KANNAGA 48 F 86/11 8 POS 1 YEAR 82 8 2 5.62 0 3 3 POSITIVE 
ANUSHYA 49 F 55/12 7 NEG 3 YEARS 25 2 0 3.05 0 1 1 NEGATIVE 
MANICKAM 40 M 660/11 7 NEG 1 YEAR 60 4 3 5.03 20 17 37 POSITIVE 
LAKSHMI 53 F 528/11 7 POS 7 MONTHS 70 4 2 4.91 0 0 0 NEGATIVE 
SELVI 43 F 49/11 8 POS 2 YEARS 30 4 1 4.76 16 8 24 POSITIVE 
VISALATCHI 48 F 321/12 7 NEG 2 YEARS 42 11 2 5.29 2 8 10 POSITIVE 
VASANTH 47 M 32/12 8 POS 1 YEAR 15 2 0 2.97 0 4 4 POSITIVE 
DEVA 38 M 34/11 7 NEG 2 YEARS 10 4 0 3.01 0 0 0 NEGATIVE 
VANITHA 44 F 50/12 7 NEG  1 YEAR 15 4 2 3.58 1 1 2 POSITIVE 
JAYARANI 55 F 35/11 7 POS 3 YEARS 10 5 2 3.82 17 12 29 POSITIVE 
MEERA  42 F 167/12 8 POS 6 MONTHS 62 5 3 5.05 0 0 0 NEGATIVE 
RAJAMANI 63 M 358/11 6 NEG 
18 
MONTHS 15 1 1 3.16 0 0 0 NEGATIVE 
MEENATCHI 35 F 39/10 7 NEG 2 YEARS 15 8 0 3.76 0 0 0 NEGATIVE 
RAGHUPATHI 42 M 113/12 7 NEG 2 YEARS 20 8 3 4.73 32 18 50 POSITIVE 
LATHA 45 F 302/11 8 POS 1 YEAR 95 17 8 6.99 10 20 30 POSITIVE 
MOHAN  50 M 303/12 7 POS 
15 
MONTHS 20 12 7 5.48 2 1 3 NEGATIVE 
KALAVATHY 62 F 352/12 8 NEG 5 YEARS 90 6 1 5.36 2 0 4 NEGATIVE 
THABITHAL 36 F 213/12 7 NEG 6 MONTHS 132 13 7 6.74 0 1 1 NEGATIVE 
MEENATCHI 70 F 88/11 7 NEG 
30 
MONTHS 93 1 1 4.57 14 8 22 NEGATIVE 
MOHANDASS 18 M 45/13 7 POS 4 MONTHS 12 12 4 4.8 0 0 0 NEGATIVE 
THAYALNAYAGI 45 F 741/12 8 POS 1 YEAR 50 10 8 5.19 0 0 0 NEGATIVE 
GEETHALAKSHMI 26 F 98/12 8 POS 
10 
MONTHS 32 8 2 4.69 0 0 0 NEGATIVE 
NAGAMMAL 60 F 235/11 8 POS 1 YEAR 36 3 1 4.18 0 3 3 POSITIVE 
NISHA 30 F 211/12 6 NEG 1 YEAR 4 8 2 3.09 0 0 0 NEGATIVE 
LALITHA 70 F 70/13 7 NEG 6 MONTHS 75 16 8 6.61 0 0 0 POSITIVE 
SHANMUGHAVALLI 43 F 95/11 9 POS 4 YEARS 10 3 0 3 0 0 0 NEGATIVE 
SUSEELA 38 F 673/12 8 POS 2 YEARS 20 4 0 4.2 24 18 42 POSITIVE 
KALAISELVI 46 F 360/12 6 NEG 1 YEAR 22 4 2 4.24 8 3 11 POSITIVE 
VINAYAGAM 30 M 53/12 6 NEG 2 YEARS 126 0 0 3.67 4 2 6 POSITIVE 
 VIJAYA 38 F 110/13 8 POS 2 YEARS 40 6 2 4.91 0 0 0 NEGATIVE 
VIMALA 57 F 541/12 6 NEG 3 YEARS 37 3 0 3.92 0 0 0 NEGATIVE 
INDRA 56 F 594/12 7 POS 4 MONTHS 40 4 0 4.26 6 8 14 POSITIVE 
KRISHNAVENI 65 F 601/12 7 NEG 1 YEAR 22 4 1 4.12 0 0 0 NEGATIVE 
CHANDRA 58 F 628/11 7 NEG 1 YEAR 54 2 0 4.14 2 2 4 POSITIVE 
RAJALAKSMI 53 F 163/11 8 POS 8 YEARS 52 3 2 4.83 42 48 90 POSITIVE 
USHNARA 43 F 152/11 6 NEG 2 YEARS 100 7 3 5.89 0 0 0 NEGATIVE 
SALMA BEEVI 52 F 75/13 6 NEG 2 YEARS 20 10 5 5.19 0 4 4 NEGATIVE 
SANTHOSH KUMAR 18 M 77/13 6 NEG 3 YEARS 12 3 1 3.13 0 0 0 NEGATIVE 
TAMARAI SELVI 35 F 200/12 7 NEG 1 YEAR 14 2 2 3.18 0 0 0 NEGATIVE 
VAIJAYANTHI 54 F 313/12 7 POS 2 YEARS 73 5 2 5.21 0 0 0 NEGATIVE 
RAJA 40 M 719/12 8 POS 5 MONTHS 67 6 4 5.43 1 0 1 NEGATIVE 
BHUVANESHWARI 35 F 128/12 7 POS 2 YEARS 65 2 0 4.13 0 0 0 NEGATIVE 
KANI 55 F 381/12 8 POS 6 YEARS 6 3 2 3.04 0 0 0 NEGATIVE 
GUNASUNDARI 44 F 476/11 7 NEG 3 YEARS 16 2 0 3.15 0 0 0 NEGATIVE 
SENGUDI 43 F 314/11 8 POS 2 YEARS 12 2 0 2.95 0 0 0 NEGATIVE 
SELVI 42 F 207/11 7 NEG 3 YEARS 42 4 0 4.16 2 1 3 POSITIVE 
KANAGI 60 F 222/11 7 NEG 3 YEARS 20 3 1 3.77 12 10 22 NEGATIVE 
KUPPAMMAL 60 F 390/11 7 NEG 4 YEARS 46 5 2 4.75 2 8 10 POSITIVE 
ALLI 43 F 295/11 7 NEG 1 YEAR 75 6 2 5.21 0 0 0 NEGATIVE 
VIJAYA 47 F 363/12 7 POS 8 MONTHS 38 4 3 4.57 4 20 24 POSITIVE 
SATHYA 35 F 55/12 8 POS 2 YEARS 10 4 0 3.15 0 0 0 NEGATIVE 
PANCHALAI 36 F 363/12 6 NEG 8  MONTHS 40 5 3 4.74 5 16 21 NEGATIVE 
SUNDAR 50 M 310/11 7 POS 2 MONTHS 44 4 1 4.47 0 0 0 NEGATIVE 
MARY 36 F 271/11 7 NEG 10 YEARS 13 2 1 3.15 16 42 58 NEGATIVE 
CHANDRAN 54 M 180/12 7 POS 1 YEAR 44 7 1 4.69 0 7 7 NEGATIVE 
LAKSHMI 70 F 89/13 7 NEG 2 YEARS 36 5 3 4.53 34 32 66 POSITIVE 
DEIVASIGNAMANI 38 M 53/11 7 NEG 1 YEAR 20 2 0 3.17 0 0 0 NEGATIVE 
MUMTAJ 30 F 113/12 9 POS 1 YEAR 105 4 3 5.14 0 0 0 NEGATIVE 
REKHA 29 F 251/12 8 POS 
18 
MONTHS 24 8 8 5.16 0 2 2 NEGATIVE 
CHITRA 52 M 28/13 7 NEG 6 MONTHS 22 2 0 3.1 0 0 0 NEGATIVE 
MUTHU 27 M 293/11 7 NEG 3 MONTHS 86 12 3 5.96 36 28 64 POSITIVE 
RAJESHWARI 45 F 298/11 6 NEG 3 YEARS 14 1 1 3.11 0 0 0 POSITIVE 
INDUMATHY 37 F 137/13 6 NEG 3 MONTHS 79 2 2 4.67 0 0 0 NEGATIVE 
LAKSHMI 54 F 138/13 8 POS 4 MONTHS 59 8 6 5.54 0 0 0 NEGATIVE 
BABY 50 F 101/10 7 NEG 10 YEARS 34 5 1 4.42 0 0 0 NEGATIVE 
ROSE 68 F 483/12 8 NEG 10 YEARS 18 3 0 3.41 0 2 2 NEGATIVE 
SAROJA 40 F 171/10 7 NEG 3 YEARS 20 3 2 3.88 0 0 0 NEGATIVE 
 SUGUNAMMA 46 F 140/13 8 POS 1 YEAR 22 6 2 4.35 0 0 0 POSITIVE 
RAJESH  27 M 464/11 8 NEG 6 YEARS 30 4 0 3.92 0 0 0 NEGATIVE 
THALAIKANI 32 M 57/13 9 POS 
18 
MONTHS 22 2 0 3.38 0 0 0 NEGATIVE 
GEETHA  46 F 126/13 6 NEG 8 MONTHS 40 3 4 4.53 2 16 18 NEGATIVE 
SUSILA 60 F 207/11 9 POS 2 YEARS 40 4 0 4.12 0 8 8 POSITIVE 
RATHINAPY 46 F 317/12 8 POS 5 MONTHS 100 2 0 4.4 2 2 4 NEGATIVE 
AMEENA 35 F 231/11 9 POS 3 YEARS 20 1 0 3.08 0 0 0 NEGATIVE 
SHAKILA 34 F 186/13 9 POS 2 YEARS 42 8 3 5.11 5 3 8 NEGATIVE 
KASIYAMMAL 50 F 611/12 7 NEG 4 YEARS 40 4 2 5.22 0 0 0 NEGATIVE 
SAMUNDESHWARAN 35 M 189/13 8 POS 6 MONTHS 20 7 5 5.18 0 2 2 NEGATIVE 
SUBHATRA 65 F 179/10 9 POS 2 YEARS 110 4 0 5.11 0 0 0 NEGATIVE 
GANGA BHARANI 65 F 174/12 9 POS 4 YEARS 50 4 2 4.95 10 12 22 NEGATIVE 
JAVED 38 M 111/12 7 NEG 3 MONTHS 60 14 4 6.08 8 8 16 POSITIVE 
THANGAPILLAI 55 M 228/13 9 POS 1 YEAR 55 10 6 5.82 0 0 0 NEGATIVE 
RAMANI 47 M 116/12 8 POS 8 MONTHS 20 8 3 4.73 0 0 0 NEGATIVE 
MEENAKUMARI 49 F 196/13 7 NEG 5 YEARS 20 9 3 4.82 0 0 0 NEGATIVE 
SUBATRA 61 F 215/13 8 POS 3 YEARS 16 0 0 2.5 0 0 0 NEGATIVE 
PANTHANAM 55 F 439/12 7 NEG 3 YEARS 25 6 4 4.59 4 20 24 NEGATIVE 
MAHESH 48 M 296/11 7 NEG 1 YEAR 42 6 3 5 0 0 0 NEGATIVE 
ASPUGI 60 F 237/13 8 NEG 3 MONTHS 22 9 6 5.23 1 1 2 POSITIVE 
ANU  37 F 323/11 9 POS 1 YEAR 125 3 1 5.33 0 0 0 NEGATIVE 
POONGAVANAM 42 F 321/12 9 POS 2 YEARS 64 9 4 5.85 0 0 0 NEGATIVE 
VELLAISAMY 47 M 171/13 7 POS 2 YEARS 42 4 4 5.28 0 0 0 NEGATIVE 
BANU 45 F 208/13 9 POS 3 YEARS 39 3 2 4.49 14 24 38 POSITIVE 
